All In Biotech

Drug Trial Radar · NCT06385925

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

570

Planned (sponsor's estimate)

Start

Apr 29, 2024

Primary completion

Oct 30, 2027

Study completion Apr 30, 2028

Sponsor

Sponsor type
Industry
First posted
Apr 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1a dose escalation/confirmation part, phase 1b dose randomization part and phase 2 dose expansion parts of TSN1611 as monotherapy or in combination with other anti-cancer therapies. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with cetuximab and FOLFIRI, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.

Conditions

  • Malignant Neoplasm

Interventions

  • TSN1611Drug

    TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

  • TSN1611Drug

    TSN1611 at the assigned dose level, orally, BID, combined with cetuximab, IV, every 2 weeks (Q2W), continuously in 28-day cycles

  • TSN1611Drug

    TSN1611 at the assigned dose level, orally, BID, combined with GnP regimen (gemcitabine and nab-paclitaxel), IV, on Day 1, 8 and 15, continuously in 28-day cycles

  • TSN1611Drug

    TSN1611 BID everyday and Patients will be administered with mFOLFOX6 on Days 1 and 2, every 2 weeks.

  • TSN1611Drug

    TSN1611 at the assigned dose level, orally, BID, combined with cetuximab and FOLFIRI (irinotecan, leucovorin, and fluorouracil), IV, every 2 weeks (Q2W), continuously in 28-day cycles,

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLTs) in phase 1 partTime frame: 21 days
  2. Objective response rate (ORR) in phase 2 partTime frame: Up to 3 years
  3. Dose limiting toxicities (DLTs) in phase 1b part of TSN1611 Combination TherapyTime frame: 28 days
  4. Objective response rate (ORR) in phase 2 part of TSN1611 Combination TherapyTime frame: Up to 3 years

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Beijing Cancer Hospital, Beijing, China

    Beijing, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, China · Not yet recruiting

  • Shanghai Chest Hospital, Shanghai, China

    Shanghai, China · Recruiting

  • Shanghai Zhongshan Hospital, Shanghai, China

    Shanghai, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • The First Affiliated Hospital of Nanchang University - Donghu District

    Nanchang, Jiang, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, Shandong, China · Recruiting

  • Ruijin Hospital-Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Sir Run Run Shaw Hospital - Zhejiang University School of Med

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital - Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.